Research Topics
| Sherene LoiSummaryAffiliation: Peter MacCallum Cancer Centre Country: Australia Publications
| Collaborators
|
Detail Information
Publications
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosisChristos Sotiriou
Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
J Natl Cancer Inst 98:262-72. 2006..We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading...
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifenSherene Loi
Functional Genomics Unit, Jules Bordet Institute, Brussels, Belgium
BMC Genomics 9:239. 2008..Independent validation was performed using 362 tamoxifen-treated ER+ BC samples obtained from multiple institutions and treated with tamoxifen only in the adjuvant and metastatic settings...- The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen responseSherene Loi
Translational Unit, Microarray Laboratories and Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
Crit Rev Oncol Hematol 61:187-94. 2007.... - Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic gradeSherene Loi
Jules Bordet Institute Machine Learning Group, Universite Libre de Bruxelles, Brussels, Belgium
J Clin Oncol 25:1239-46. 2007..However, although the basal and the ErbB2 subtypes are repeatedly recognized, identification of estrogen receptor (ER) -positive subtypes has been inconsistent. Therefore, refinement of their molecular definition is needed... 
Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysisMichail Ignatiadis
Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
J Clin Oncol 30:1996-2004. 2012..To investigate the association between chemotherapy response and gene expression modules describing important biologic processes and druggable oncogenic pathways in breast cancer (BC) subtypes...- Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation seriesChristine Desmedt
Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
Clin Cancer Res 13:3207-14. 2007..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment... - A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpointsDebora Fumagalli
Breast Cancer Translational Research Laboratory, Faculty of Medicine, Universite Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium
Lancet Oncol 13:e240-8. 2012..We expect that implementation of these recommendations will improve the conduct, reporting, and effectiveness of clinical trials and fully exploit the clinical and scientific potential of the neoadjuvant setting in breast cancer... - Dissecting the heterogeneity of triple-negative breast cancerOtto Metzger-Filho
Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
J Clin Oncol 30:1879-87. 2012.... - Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trialJan Bogaerts
Medical Oncology and Translational Research, Jules Bordet Institute, Boulevard de Waterloo 125, 1000 Brussels, Belgium
Nat Clin Pract Oncol 3:540-51. 2006..We hope that this article will trigger further discussion about the difficulties of setting up and analyzing trials aimed at establishing the worth of new methods for better selection of patients for cancer treatment... - Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancerMarc Buyse
International Drug Development Institute, Brussels, Belgium
J Natl Cancer Inst 98:1183-92. 2006..88 and 0.89, respectively. CONCLUSIONS: The 70-gene signature adds independent prognostic information to clinicopathologic risk assessment for patients with early breast cancer... - Beyond trastuzumab: new treatment options for HER2-positive breast cancerKamal S Saini
Breast International Group, Brussels, Belgium
Breast 20:S20-7. 2011..Therefore, to avoid unnecessary toxicities and costs, it is critical to intensify the research for biomarkers that can identify those patients most likely to benefit from specific targeted therapies... - Elucidating prognosis and biology of breast cancer arising in young women using gene expression profilingHatem A Azim
Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
Clin Cancer Res 18:1341-51. 2012..Breast cancer in young women is associated with poor prognosis. We aimed to define the role of gene expression signatures in predicting prognosis in young women and to understand biological differences according to age... - Breast cancer gene expression profiling: clinical trial and practice implicationsSherene Loi
Jules Bordet Institute, Microarray Laboratories, Department of Medical Oncology, 121 Boulevard de Waterloo, Brussels 1000, Belgium
Pharmacogenomics 6:49-58. 2005..This will lead, ultimately, to the application of user-friendly tools derived from this technology to everyday patient care... - Clinical application of the 70-gene profile: the MINDACT trialFatima Cardoso
Jules Bordet Institute, Blvd de Waterloo, 125, 1000 Brussels, Belgium
J Clin Oncol 26:729-35. 2008..This article reviews the several steps in the development of the profile from its discovery to its clinical validation... - Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen typesSherene Loi
Breast International Group, and Breast Cancer Translational Research Laboratory, Institute Jules Bordet, Brussels, Belgium
Lancet Oncol 12:1162-8. 2011..If possible, patients should be referred at the outset to specialised centres to give them the opportunity to participate in neoadjuvant clinical trials, thereby avoiding several biopsy procedures... - Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?Dimitrios Zardavas
BrEAST Data Center, Institut Jules Bordet, Brussels, Belgium
Curr Opin Oncol 24:623-34. 2012..We review these findings in the context of the preclinical data and the current status of biomarker development in this field... - PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancerSherene Loi
Breast Cancer Translational Research Laboratory, Jules Bordet Institute, Brussels, Belgium
PLoS ONE 8:e53292. 2013..Further evaluation of the PIK3CA-GS as a predictive biomarker is warranted as it may facilitate better selection of responsive patient populations for mTOR inhibition in combination with letrozole... - HER2-overexpressing breast cancer: time for the cure with less chemotherapy?Sherene Loi
Breast Cancer Translational Research Laboratory, Institut Jules Bordet, l Université Libre de Bruxelles, Brussels, Belgium
Curr Opin Oncol 23:547-58. 2011..We review these findings and reflect on how they may influence the next generation of clinical trials in this breast cancer subtype... - Challenges in breast cancer clinical trial design in the postgenomic eraSherene Loi
Translational Research Unit, Jules Bordet Institute, 121 Boulevard de Waterloo, Brussels 1000, Belgium
Curr Opin Oncol 16:536-41. 2004..The success of new approaches in BC research critically depends on well-conducted translational research linked to prospective clinical trials, and international collaboration, bringing together human and technological resources... - Molecular forecasting of breast cancer: time to move forward with clinical testingSherene Loi
J Clin Oncol 24:721-2; author reply 722-3. 2006 - Obesity and outcomes in premenopausal and postmenopausal breast cancerSherene Loi
Peter MacCallum Cancer Centre, 723 Swanston Street, Carlton, Victoria 3053, Australia
Cancer Epidemiol Biomarkers Prev 14:1686-91. 2005..Given the high and increasing prevalence of obesity in western countries, more research on improving the treatment of obese breast cancer patients is warranted...